Papillary NMIBC could become the next commercial test for ImmunityBio’s ANKTIVA franchise
ANKTIVA already has an NMIBC foothold. The harder test is whether FDA reviewers accept extrapolation into papillary-only disease.
Pharma & Biotech
Pharma & Biotech
Phoenix and Raven launch direct-to-patient generic semaglutide after Health Canada approval
Generic semaglutide is cheaper, but access is now the real battleground. Phoenix and Raven are testing Canada’s GLP-1 telehealth future.
Pharma & Biotech
How Codexis, Inc.’s ECO Synthesis platform could reshape industrial RNA production workflows
Explore why Codexis, Inc.’s latest RNA manufacturing advances could influence scalability, stereochemical control, and future siRNA production economics.
Pharma & Biotech
Could Hyundai Bioscience’s XAFTY become a crisis-response antiviral for Ebola and hantavirus?
Ebola urgency is rising, but broad-spectrum antivirals still face a proof gap. Hyundai Bioscience’s XAFTY now enters that debate.
Pharma & Biotech
How Araceli Biosciences is pushing live-cell imaging into ultra-high-throughput drug screening
AI drug discovery needs dynamic biology, not static snapshots. Araceli Biosciences is betting Endeavor Live Cell can close that data gap.
Pharma & Biotech
Regeneron’s $2.2bn Parabilis pact signals rising interest in next-generation conjugates
ADCs changed cancer delivery. Regeneron and Parabilis now want Helicon peptides to push conjugates inside harder-to-drug biology.
Pharma & Biotech
Samsung Bioepis targets Japan’s autoimmune market with ustekinumab biosimilar debut
Japan needs lower biologic costs. Samsung Bioepis’s NIPRO launch tests whether ustekinumab biosimilars can shift autoimmune care.
Pharma & Biotech
Bayer’s asundexian FDA priority review puts Factor XIa inhibition closer to a real stroke prevention test
Bayer needs a new cardiovascular growth engine. Asundexian’s FDA priority review now tests whether Factor XIa can move from promise to practice.
Pharma & Biotech
Genentech’s ASCO 2026 data puts giredestrant at the centre of Roche’s breast cancer strategy
Endocrine therapy is crowded. Genentech needs giredestrant to prove it can shift breast cancer care, not just add another option.
Pharma & Biotech
Can Tyvaso change the treatment pathway for idiopathic pulmonary fibrosis after TETON-1?
IPF has few durable treatment options. Tyvaso’s TETON data may test whether inhaled therapy can reset the regulatory and commercial playbook.